Expedeon has signed an agreement with Sona Nanotech to address limitations in the development of complex, multiplex point-of-care (POC) lateral flow assay (LFA) diagnostic tests.

Under the terms of the commercial agreement, Expedeon will provide gold nanoparticle, bioconjugation technologies, while Sona will offer its lateral flow assay development services.

As part of the partnership, the companies will develop complex / multiplex immunoassays into LFAs, from proof of principle, through scale-up and transfer, to manufacturing.

Expedeon CEO Dr Heikki Lanckriet said: “The adoption of point-of-care diagnostics is increasing globally, due to factors such as high prevalence of infectious diseases in developing countries, increasing incidence of target diseases, and rising preference for home healthcare.

“Despite the growing market, there are several bottlenecks in the development of point of care assays. We are looking forward to working with Sona to overcome these challenges, without compromising on quality or reproducibility.”

The collaboration between Expedeon and Sona will address the challenges in both development and transfer to manufacturing that have earlier limited the number of multiplex lateral flow assays brought to the market.

This would enable detection of multiple analytes with distinct visual differences between the test lines, simultaneously.

Sona Nanotech president and CEO Darren Rowles said: “Signing this agreement with Expedeon further strengthens the productive partnership between our organisations and our commitment to delivering value to our combined global customer base.”

The lateral flow assay market, which consists of stakeholders such as raw material suppliers, processors, end-product manufacturers, distributors, and regulatory organisations, is expected to reach $8.7bn by 2023 from an estimated $6bn last year, according to a recent market research report.